Yarrow Bioscience Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Yarrow Bioscience Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.316 $ to 42.90 $ · Last price: 25.50 $ (As of: September 25, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/25/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Yarrow Bioscience Inc YARW | 0.1 | – | 0.0 | – | 0.0 | 13.8 | 188.6 |
| Vertex Pharmaceuticals Inc VRTX | 133.1 | 31.9 | 24.4 | 55.0 | 38.1 | 9.6 | 37.8 |
| Regeneron Pharmaceuticals Inc REGN | 81.9 | 19.8 | 13.5 | 44.5 | 20.7 | 1.0 | 38.7 |
| Moderna Inc MRNA | 78.9 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| argenx NV ARGX | 59.7 | 36.7 | 31.5 | 59.1 | 32.0 | 89.6 | 31.9 |
| Revolution Medicines Inc RVMD | 42.6 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.0 |
| BeiGene, Ltd. ONC | 40.8 | 64.4 | 32.4 | 88.9 | 19.1 | 40.2 | 9.1 |
| Alnylam Pharmaceuticals Inc ALNY | 34.0 | 64.4 | 28.6 | 79.7 | 23.0 | 65.2 | -45.6 |
| Royalty Pharma Plc RPRX | 32.1 | 31.4 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 42.6 | 34.3 | 19.2 | 57.0 | 20.7 | 9.6 | 38.7 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1 | -14 | -14 | -2,204.32 | -2 | -29 | 42 |
| 2017 | 5 | -30 | -29 | -4,555.94 | -28 | -57 | 67 |
| 2018 | 11 | -55 | -51 | -8,547.10 | -53 | 130 | 140 |
| 2019 | 0 | -76 | -70 | -7,474.70 | -65 | 69 | 79 |
| 2020 | 21 | 253 | -256 | -7,095.37 | -137 | 37 | 94 |
| 2021 | 1 | -39 | -73 | -1,282.45 | -56 | 49 | 67 |
| 2022 | 0 | -34 | -23 | -364.26 | -29 | 31 | 41 |
| 2023 | 0 | -29 | -28 | -138.48 | -25 | 89 | 98 |
| 2024 | 1 | -44 | -40 | -46.77 | -34 | 52 | 67 |
| 2025 | 1 | -30 | -26 | -30.96 | -33 | 28 | 30 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q2 | -11.04 | 92.80 | 0 | 46.70 | -4,750.50 | -9 | -9 |
| 2024: Q3 | -14.27 | 85.80 | 0 | 6.10 | -10,047.10 | -9 | -9 |
| 2024: Q4 | -14.11 | -41.60 | 0 | 10.50 | -14,311.90 | -9 | -9 |
| 2025: Q1 | -10.09 | -37.50 | 0 | 106.10 | -4,262.90 | -12 | -12 |
| 2025: Q2 | -6.73 | 39.10 | 0 | -65.20 | -8,340.60 | -11 | -11 |
| 2025: Q3 | -8.50 | 40.40 | 0 | 39.70 | -4,307.70 | -7 | -7 |
| 2025: Q4 | – | – | 0 | 54.80 | -3,720.80 | -4 | -4 |
| 2026: Q1 | -4.19 | 58.50 | 0 | -57.40 | -4,168.60 | -4 | -4 |
| 2026: Q2 | -3.51 | 47.80 | 0 | 0.00 | -3,000.00 | -2 | -2 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Growth
Breakout & Setup
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.45 | -1.45 – -1.45 | 0 | – | 1 |
| 12/31/2027 | -1.65 | -1.65 – -1.65 | 0 | -13.8% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 6.1%
- More than 10% revenue growth is expected for the coming year -100.0%
- Share count grows by less than 3% a year 137.6%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -5,797.5%
- Gross margin at 40% or higher and without meaningful erosion 96.0%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 29 m net cash
- Operating cash flow covers the profits of the last three years 2 m
- Return on capital at 15% or higher, or up versus two years ago -107.2%
- Insiders hold at least 10% or are net buyers 4.5%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -1.8%
- Exp. sales growth 3Y > 5% -100.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -100.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -95.4%
- ROCE > 15% -107.1%
- Expected return > 10% -100.0%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Yarrow Bioscience, Inc. ist ein klinisches Biotechnologieunternehmen, das transformative Therapien für Autoimmunerkrankungen der Schilddrüse entwickelt. Der Kandidat des Unternehmens, YB-101, ist ein humanisierter monoklonaler Antikörper, der auf den Thyreoidea-stimulierendes-Hormon-Rezeptor (TSHR) zur Behandlung von Morbus Basedow und endokriner Orbitopathie abzielt. Das Unternehmen wurde 2025 gegründet und hat seinen Sitz in New York, New York.
- Employees
- 7
- Headquarters
- New York, NY
- Address
- 40 10 th Avenue, 10014 New York, United States
- Website
- yarrowbioscience.com
- IPO Date
- 01/25/2018
- ISIN
- US92941V4077
- Stock Split
- 1:50 on 07/27/2026
- Stock Split
- 1:18 on 02/13/2023
- Stock Split
- 1:4 on 02/16/2021
Management
| Name | Title | Birth Year |
|---|---|---|
| Rebecca Velez Frey Pharm.D. | President, CEO & Director | – |
| Tyler Zeronda CPA | Chief Financial Officer | 1986 |
| Rachael Alford Ph.D. | Chief Operating Officer | – |
| Lori Payton Ph.D. | Chief Development Officer | – |
| Steven W. Ryder F.A.C.P, M.D. | Chief Medical Officer | 1951 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.